CC-99712 is an antibody-drug conjugate (ADC) with anti-BCMA antibody that binds to BCMA on tumor cell surfaces causing cell cycle arrest and inducing antibody-dependent cellular cytotoxicity (ADCC).

SparkCures ID 358
Developed By Celgene Corporation, a wholly owned subsidiary of Bristol Myers Squibb
Generic Name CC-99712
Treatment Classifications
Treatment Targets

Clinical Trials


There are no resources, links or videos to display for this treatment.